Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61P - Specific therapeutic activity of chemical compounds or medicinal preparations › A61P 25 - Drugs for disorders of the nervous system
Patents for A61P 25 - Drugs for disorders of the nervous system (183,225)
06/2000
06/29/2000WO2000037059A2 Compositions and methods to inactivate n-type calcium channels
06/29/2000WO2000037058A1 Transparent transdermal nicotine delivery devices
06/29/2000WO2000037055A1 Controlled release formulation of divalproex sodium
06/29/2000WO2000010973A3 Oxo-pyridoimidazole-carboxamides: gaba brain receptor ligands
06/29/2000WO2000002543A3 Antihypersensitive combination of valsartan and calcium channel blocker
06/29/2000WO2000000610A3 Human signal peptide-containing proteins
06/29/2000WO2000000594A3 Human transferases
06/29/2000WO1999064034A9 β2-ADRENERGIC RECEPTOR AGONISTS
06/29/2000DE19859636A1 Kontrolliert freisetzende pharmazeutische Zusammensetzung mit Tilidinmesylat als Wirkstoff A controlled release pharmaceutical composition comprising as an active ingredient tilidine mesylate
06/29/2000CA2358086A1 Protein-protein interactions in neurodegenerative disorders
06/29/2000CA2356736A1 Use of etherlysophospholipids as antiinflammatory agents
06/29/2000CA2356460A1 Compounds, methods of screening and methods of treatment for central and peripheral nervous system disorders
06/29/2000CA2356454A1 Compounds for intracellular delivery of therapeutic moieties to nerve cells
06/29/2000CA2356246A1 Use of 5ht3-receptor antagonists for the treatment of chronic fatigue syndrome
06/29/2000CA2356181A1 Triazineone compounds for treating diseases due to sarcocystis, neospora and toxoplasma
06/29/2000CA2356174A1 Kidney disease detection and treatment
06/29/2000CA2356134A1 Sulfonyloxazolamines as therapeutic active compounds
06/29/2000CA2355882A1 Mammalian cell preparations optionally transfected with a gene coding for an active substance containing same
06/29/2000CA2355861A1 Amide and urea derivatives as 5-ht reuptake inhibitors and as 5-ht1b/1d ligands
06/29/2000CA2355704A1 Melatonin derivatives and medicine containing same
06/29/2000CA2355163A1 Three dimensional structure of a sterile alpha motif domain
06/29/2000CA2355137A1 Non-peptide nk1 receptors antagonists
06/29/2000CA2355074A1 Lymphocytic membrane proteins
06/29/2000CA2354846A1 Method of enhancing the biological activity of ligands
06/29/2000CA2354074A1 Method of identifying a psychotropic agent using differential gene expression
06/29/2000CA2353907A1 Fused 1,2,4-thiadiazine derivatives, their preparation and use
06/29/2000CA2352624A1 Method of using steam ironing of fabrics as a way of causing reduction of physiological and/or subjective reactivity to stress in humans
06/28/2000EP1013275A2 Method and compositions for treating hypertension, angina and other disorders using optically pure (-) amlodipine
06/28/2000EP1012308A1 Compounds, compositions and methods for the endocytic presentation of immunosuppressive factors
06/28/2000EP1012296A2 Mammalian thioredoxin
06/28/2000EP1012288A1 Novel human cystatin-like protein
06/28/2000EP1012278A1 Murine and human cerberus-like proteins and compositions comprising them
06/28/2000EP1012273A2 Secreted proteins and polynucleotides encoding them
06/28/2000EP1012267A2 An antisense oligonucleotide preparation method
06/28/2000EP1012185A1 Retro-inverso neurotrophic and analgesic peptides
06/28/2000EP1012177A1 Estrogen receptor
06/28/2000EP1012162A4 Soluble proteins
06/28/2000EP1012162A1 Soluble proteins
06/28/2000EP1012151A1 Heterocyclyl-substituted ring-fused pyridines and pyrimidines as corticotropin releasing hormone (crh) antagonists, useful for treating cns and stress-related disorders
06/28/2000EP1012145A1 Alkoxy-substituted compounds, methods, and compositions for inhibiting parp activity
06/28/2000EP1011732A1 Lineage-restricted neuronal precursors
06/28/2000EP1011712A2 Cytokines having neurotrophic activity
06/28/2000EP1011711A1 Synergistic effects of op/bmp morphogens and gdnf/ngf neurotrophic factors
06/28/2000EP1011709A1 Inhibition of apoptotis using prosaposin receptor agonists
06/28/2000EP1011683A1 Vitamin d analogues and their neuronal effects
06/28/2000EP1011680A2 Controlled release microsphere delivery system
06/28/2000EP1011679A1 Use of 2,3,4,5-tetrahydro-1h-3-benzazepines for the manufacture of a pharmaceutical composition for the treatment of sleep disorders
06/28/2000EP1011677A1 4-aryl-3-aminoquinoline-2-one derivatives as potassium channel modulators
06/28/2000EP1011671A1 Substance dependence treatment using opiate antagonists and serotonin compounds
06/28/2000EP1011662A1 Improved compositions and methods for the control of smoking
06/28/2000EP1011647A1 Spray formulations of antihyperalgesic opiates and method of treating topical hyperalgesic conditions and pruritus therewith
06/28/2000EP1011644A1 Methods and apparatus for treatment of parkinson's disease
06/28/2000EP1011637A1 Modulation of drug loading in multivesicular liposomes
06/28/2000EP1011330A1 Central nervous system axon regeneration
06/28/2000EP1011327A1 Treatment or prophylaxis of retinal pathology and spinal cord injury
06/28/2000EP0866719B1 Method for treating retinal ganglion cell injury using glial cell line-derived neurotrophic factor (gdnf) protein product
06/28/2000EP0639224B1 Lectin domain variants of selectin
06/28/2000CN1258290A Salt
06/28/2000CN1257871A Somatostatin polypeptide analog and its application
06/28/2000CN1257864A Imidazoline compound, preparing process thereof and pharmaceutical composition contg. same
06/28/2000CN1257734A Sobering-up health-care beverage
06/28/2000CN1257730A Preparation containing peanut leaf extract and its preparing process
06/28/2000CN1257721A Liquid medicine for giving up smoking and its preparing process
06/28/2000CN1257717A Powder medicine for eliminating wind cold and stagnant heat
06/28/2000CN1053898C Process for preparation of 2-{4-[4-(4-loro-1-pyrazolyl) butyl]-1-piperazinyl} pyrimidine
06/28/2000CN1053813C Health-care medicinal core and its preparation method
06/27/2000US6080873 Fused pyrrolecarboxamides; a new class of GABA brain receptor ligands
06/27/2000US6080841 Human induced tumor protein
06/27/2000US6080790 Selective and potent inhibitors of phosphodiesterase iv and are useful for the prophylaxis and treatment of inflammatory diseases and the alleviation of conditions associated with central nervous malfunction
06/27/2000US6080781 Dissolving tetralone or benzopyranone compounds and a benzaldehyde compound in organic solvent, refluxing with heating under acidic condition and purifying the reactio product; useful for treating hormone dependent disease
06/27/2000US6080780 Use of nitroflavonoids for the treatment of anxiety
06/27/2000US6080778 Methods for decreasing beta amyloid protein
06/27/2000US6080776 Used as a microbiocide for crop protection
06/27/2000US6080773 Benzylamine derivatives which are useful in treating psychiatric disorders
06/27/2000US6080764 Superoxide radical inhibitor
06/27/2000US6080758 Analgesics, antiinflammatory agents; asthma; allergic rhinitis
06/27/2000US6080754 For treatment and prophylaxis of estrogen related syndromes and disorders
06/27/2000US6080752 For treating condition which requires antagonism of a dopamine receptor such as psychtic condition
06/27/2000US6080745 For treating or preventing disorders of dopamine system, such as schizophrenia
06/27/2000US6080743 2,3-dioxo-1,2,3,4-tetrahydro-quinoxalinyl derivatives
06/27/2000US6080740 Spiro-ketal derivatives and their use as therapeutic agents
06/27/2000CA2198564C Method of reducing tissue damage associated with non-cardiac ischemia
06/27/2000CA2188427C Neurotransmitter release enhancers
06/27/2000CA2017193C N-(aryloxyalkyl)heteroarylpiperidines and-heteroarylpiperazines, a pro cess for their preparation and their use as medicaments
06/22/2000WO2000035948A1 Methods and compositions for treating disorders involving excitotoxicity
06/22/2000WO2000035937A1 47 human secreted proteins
06/22/2000WO2000035922A1 2,3,4,4a-tetrahydro-1h-pyrazino(1,2-a)quinoxalin-5(6h)one derivates being 5ht2c agonists
06/22/2000WO2000035921A1 4,5-pyrazinoxindoles as protein kinase inhibitors
06/22/2000WO2000035919A2 Quinoline derivatives
06/22/2000WO2000035915A1 Piperazine derivatives
06/22/2000WO2000035910A1 Derivative of paroxetine
06/22/2000WO2000035907A1 Imidazolones and their use in treating benign prostatic hyperplasia and other disorders
06/22/2000WO2000035892A1 Piperazine ethylamide derivatives with 5-ht1a receptor activity
06/22/2000WO2000035891A1 Morpholinone and morpholine derivatives and uses thereof
06/22/2000WO2000035882A1 1,2,3,4-tetrahydronaphthalenes and their pharmaceutical use
06/22/2000WO2000035878A1 1,4-piperazine derivatives having 5ht1a receptor activity
06/22/2000WO2000035875A1 Arylpiperidine and aryl-1,2,5,6-tetrahydropyridine urea derivatives having 5ht1a receptor activity
06/22/2000WO2000035874A1 Arylpiperidine and aryl-1,2,5,6-tetrahydropyridine amide derivatives having 5ht1a receptor activity
06/22/2000WO2000035873A1 Process for preparation of paroxetine maleate
06/22/2000WO2000035855A1 3,4-diamino-3-cyclobutene-1,2-dione derivatives which inhibit leukocyte adhesion mediated by vla-4
1 ... 1499 1500 1501 1502 1503 1504 1505 1506 1507 1508 1509 1510 1511 1512 1513 1514 1515 1516 1517 1518 1519 ... 1833